Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer, July 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 104 articles:
HTML format


 

Single Articles

  1. APFELBECK M, Grimm T, Kretschmer A, Buchner A, et al
    Follow-up of high-risk bladder cancer-Is it safe to perform fluorescence endoscopy multiple times in the same patient?
    Urol Oncol. 2017 Jun 27. pii: S1078-1439(17)30262.
    Abstract    

    Abstract available

  2. GARRY EM, Buse JB, Lund JL, Pate V, et al
    Comparative Safety of Pioglitazone versus Clinically Meaningful Treatment Alternatives on the Risk of Bladder Cancer in Older US Adults with Type 2 Diabetes.
    Diabetes Obes Metab. 2017 Jun 29. doi: 10.1111/dom.13049.
    Abstract    

    Abstract available

  3. NOROHEIMER S, Ozalvo R, Abramovich A, Fenig E, et al
    [THE MULTIDISCIPLINARY MUSCLE INVASIVE BLADDER CANCER CLINIC AT THE RABIN MEDICAL CENTER].
    Harefuah. 2017;:349-352.
    Abstract    



  4. WANG SC, Sung WW, Kao YL, Hsieh TY, et al
    The gender difference and mortality-to-incidence ratio relate to health care disparities in bladder cancer: National estimates from 33 countries.
    Sci Rep. 2017;7:4360.
    Abstract    

    Abstract available

  5. SOMASEKAR R, Naganathbabu O, Prabhakaran R, Gnanasekar M, et al
    Salvage Surgery for Metastatic Gall Bladder Cancer with Vanishing Liver Metastasis Following Palliative 5-Fluorouracil Metronomic Chemotherapy.
    J Clin Diagn Res. 2017;11:XD03-XD05.
    Abstract    

    Abstract available

  6. WEI Z, Hu X, Liu J, Zhu W, et al
    MicroRNA-497 upregulation inhibits cell invasion and metastasis in T24 and BIU-87 bladder cancer cells.
    Mol Med Rep. 2017 Jun 19. doi: 10.3892/mmr.2017.6805.
    Abstract    

    Abstract available

  7. MENG XY, Shi MJ, Chen JF, Liao Y, et al
    Association between the TACC3 rs798766 Polymorphism and Risk of Urinary Bladder Cancer: A Synthesis Based on Current Evidence.
    Dis Markers. 2017;2017:7850708.
    Abstract    

    Abstract available

  8. WHANG YM, Jin SB, Park SI, Chang IH, et al
    MEK inhibition enhances efficacy of bacillus Calmette-Guerin on bladder cancer cells by reducing release of toll-like receptor 2-activated antimicrobial peptides.
    Oncotarget. 2017 May 26. doi: 10.18632/oncotarget.18230.
    Abstract    

    Abstract available

  9. KUNATH F
    [Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer : Comment on a recently published Cochrane Review].
    Urologe A. 2017 Jun 26. doi: 10.1007/s00120-017-0436.
    Abstract    



  10. TRABOULSI SL, Brimo F, Yang Y, Maedler C, et al
    Pathology review impacts clinical management of patients with T1-T2 bladder cancer.
    Can Urol Assoc J. 2017;11:188-193.
    Abstract    

    Abstract available

  11. KLAASSEN Z, Li K, Kassouf W, Black PC, et al
    Contemporary cost-consequence analysis of blue light cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
    Can Urol Assoc J. 2017;11:173-181.
    Abstract    

    Abstract available

  12. MANIG L, Janssen S, Schild SE, Rades D, et al
    A New Prognostic Tool for Patients Undergoing Radiotherapy plus Upfront Transurethral Resection for Bladder Cancer.
    In Vivo. 2017;31:745-748.
    Abstract    

    Abstract available

  13. CHEVALIER MF, Trabanelli S, Racle J, Salome B, et al
    ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.
    J Clin Invest. 2017 Jun 26. pii: 89717. doi: 10.1172/JCI89717.
    Abstract    

    Abstract available

  14. ATTALLA K, Kent M, Waingankar N, Mehrazin R, et al
    Robotic-assisted radical cystectomy versus open radical cystectomy for management of bladder cancer: review of literature and randomized trials.
    Future Oncol. 2017;13:1195-1204.
    Abstract    

    Abstract available

  15. LI C, Cui Y, Liu LF, Ren WB, et al
    High Expression of Long Noncoding RNA MALAT1 Indicates a Poor Prognosis and Promotes Clinical Progression and Metastasis in Bladder Cancer.
    Clin Genitourin Cancer. 2017 May 10. pii: S1558-7673(17)30125.
    Abstract    

    Abstract available

  16. MIYAKE M, Morizawa Y, Hori S, Marugami N, et al
    Integrative Assessment of Pretreatment Inflammation-, Nutrition-, and Muscle-Based Prognostic Markers in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy.
    Oncology. 2017 Jun 24. doi: 10.1159/000477405.
    Abstract    

    Abstract available

  17. WILLIAMS SB, Huo J, Dafashy TJ, Ghaffary CK, et al
    Survival differences among patients with bladder cancer according to sex: Critical evaluation of radical cystectomy use and delay to treatment.
    Urol Oncol. 2017 Jun 21. pii: S1078-1439(17)30252.
    Abstract    

    Abstract available

  18. YANG Y, Guo JX, Shao ZQ, Gao JP, et al
    Matrine inhibits bladder cancer cell growth and invasion in vitro through PI3K/AKT signaling pathway: An experimental study.
    Asian Pac J Trop Med. 2017;10:515-519.
    Abstract    

    Abstract available

  19. FITZPATRICK R, Paterson NR, Belanger EC, McCurdy A, et al
    Primary amyloidosis of the bladder; a mimicker of bladder cancer.
    Can J Urol. 2017;24:8868-8870.
    Abstract    

    Abstract available

  20. MORALES A
    BCG: A throwback from the stone age of vaccines opened the path for bladder cancer immunotherapy.
    Can J Urol. 2017;24:8788-8793.
    Abstract    

    Abstract available

  21. CAKIR E, Kucuk U, Pala EE, Sezer O, et al
    Cytopathologic differential diagnosis of low-grade urothelial carcinoma and reactive urothelial proliferation in bladder washings: a logistic regression analysis.
    APMIS. 2017;125:431-436.
    Abstract    

    Abstract available

  22. ESKAROS AR, Egloff SA, Boyd KL, Richardson JE, et al
    Larger core size has superior technical and analytical accuracy in bladder tissue microarray.
    Lab Invest. 2017;97:335-342.
    Abstract    

    Abstract available

  23. ZIMMERMANN M, Wang SS, Zhang H, Lin TY, et al
    Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.
    Mol Cancer Ther. 2017;16:376-387.
    Abstract    

    Abstract available

  24. BI H, Zhang Z, Guo L, Fu C, et al
    Effect of wound fluid on chemotherapy sensitivity of T24 bladder cancer cells with different enhancer of zeste homolog 2 status.
    Oncotarget. 2017 Jun 28. doi: 10.18632/oncotarget.18791.
    Abstract    

    Abstract available

  25. VAN OSCH FHM, Pauwels CGGM, Jochems SHJ, Fayokun R, et al
    Tar, nicotine and carbon monoxide yield of UK cigarettes and the risk of non-muscle-invasive and muscle-invasive bladder cancer.
    Eur J Cancer Prev. 2017 Jul 4. doi: 10.1097/CEJ.0000000000000404.
    Abstract    

    Abstract available

  26. SHIN SS, Song JH, Hwang B, Park SL, et al
    Angiopoietin-like protein 4 potentiates DATS-induced inhibition of proliferation, migration, and invasion of bladder cancer EJ cells; involvement of G2/M-phase cell cycle arrest, signaling pathways, and transcription factors-mediated MMP-9 expression.
    Food Nutr Res. 2017;61:1338918.
    Abstract    

    Abstract available

  27. KIKUCHI K, Shigihara T, Hashimoto Y, Miyajima M, et al
    Apparent diffusion coefficient on magnetic resonance imaging (MRI) in bladder cancer: relations with recurrence/progression risk.
    Fukushima J Med Sci. 2017 Jul 5. doi: 10.5387/fms.2017.
    Abstract    

    Abstract available

  28. LIU Q, Diao R, Feng G, Mu X, et al
    Risk score based on three mRNA expression predicts the survival of bladder cancer.
    Oncotarget. 2017 Jun 27. doi: 10.18632/oncotarget.18642.
    Abstract    

    Abstract available

  29. GOZEN AS, Umari P, Scheitlin W, Su FE, et al
    Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer.
    Arch Ital Urol Androl. 2017;89:102-105.
    Abstract    

    Abstract available

  30. ROBINSON ARL, Radhakrishnan R, Horvath R, Pandey S, et al
    A case of disseminated Mycobacterium bovis 2 years post-intravesicular Bacillus Calmette-Guerin therapy for superficial urinary bladder cancer.
    Intern Med J. 2017;47:820-823.
    Abstract    

    Abstract available

  31. TRINH TW, Glazer DI, Sadow CA, Sahni VA, et al
    Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results.
    Abdom Radiol (NY). 2017 Jul 4. doi: 10.1007/s00261-017-1249.
    Abstract    

    Abstract available

  32. MBATCHI LC, Gassiot M, Pourquier P, Goberna A, et al
    Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer.
    Cancer Chemother Pharmacol. 2017 Jul 4. doi: 10.1007/s00280-017-3379.
    Abstract    

    Abstract available

  33. LOBO N, Mount C, Omar K, Nair R, et al
    Landmarks in the treatment of muscle-invasive bladder cancer.
    Nat Rev Urol. 2017 Jul 4. doi: 10.1038/nrurol.2017.
    Abstract    

    Abstract available

  34. DAVIS RL 3RD, Le W, Cui Z
    Granulocytes as an effector mechanism of BCG therapy for bladder cancer.
    Med Hypotheses. 2017;104:166-169.
    Abstract    

    Abstract available

  35. CHEN Y, Xie H, Zou Y, Lai X, et al
    Tetracycline-controllable artificial microRNA-HOTAIR + EZH2 suppressed the progression of bladder cancer cells.
    Mol Biosyst. 2017 Jul 3. doi: 10.1039/c7mb00202.
    Abstract    

    Abstract available

  36. FARINA MS, Lundgren KT, Bellmunt J
    Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Drugs. 2017;77:1077-1089.
    Abstract    

    Abstract available

  37. KE K, Li H, Yao H, Shi XN, et al
    In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of FGFR3 and a candidate anticancer drug for bladder carcinoma.
    Chem Biol Drug Des. 2017;89:505-513.
    Abstract    

    Abstract available

  38. CHEN MC, Hsu WL, Chang WL, Chou TC, et al
    Antiangiogenic activity of phthalides-enriched Angelica Sinensis extract by suppressing WSB-1/pVHL/HIF-1alpha/VEGF signaling in bladder cancer.
    Sci Rep. 2017;7:5376.
    Abstract    

    Abstract available

  39. CORFIELD JM, Lawrentschuk N
    Health information quality on the internet for bladder cancer and urinary diversion: a multi-lingual analysis.
    Minerva Urol Nefrol. 2017 Jul 12. doi: 10.23736/S0393-2249.17.02952.
    Abstract    

    Abstract available

  40. POURSANI EM, Mehravar M, Mohammad Soltani B, Mowla SJ, et al
    A Novel Variant of OCT4 Entitled OCT4B3 is Expressed in Human Bladder Cancer and Astrocytoma Cell Lines.
    Avicenna J Med Biotechnol. 2017;9:142-145.
    Abstract    

    Abstract available

  41. YE T, Ding W, Wang N, Huang H, et al
    Long noncoding RNA linc00346 promotes the malignant phenotypes of bladder cancer.
    Biochem Biophys Res Commun. 2017 Jul 10. pii: S0006-291X(17)31387.
    Abstract    

    Abstract available

  42. SHI J, Wang Y, Jia Z, Gao Y, et al
    Curcumin inhibits bladder cancer progression via regulation of beta-catenin expression.
    Tumour Biol. 2017;39:1010428317702548.
    Abstract    

    Abstract available

  43. POP-BICA C, Gulei D, Cojocneanu-Petric R, Braicu C, et al
    Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets.
    Int J Mol Sci. 2017;18.
    Abstract    

    Abstract available

  44. HUANG X, Zhuang C, Zhuang C, Xiong T, et al
    An enhanced hTERT promoter-driven CRISPR/Cas9 system selectively inhibits the progression of bladder cancer cells.
    Mol Biosyst. 2017 Jul 12. doi: 10.1039/c7mb00354.
    Abstract    

    Abstract available

  45. SONG Y, Zhang P, Sun Y, Li X, et al
    AMPK activation-dependent autophagy compromises oleanolic acid-induced cytotoxicity in human bladder cancer cells.
    Oncotarget. 2017 Jul 4. doi: 10.18632/oncotarget.18980.
    Abstract    

    Abstract available

  46. HOHNE S, Gerullis H, Blaszkewicz M, Selinski S, et al
    N-acetyltransferase 1*10 genotype in bladder cancer patients.
    J Toxicol Environ Health A. 2017 Jul 11:1-6. doi: 10.1080/10937404.2017.1304727.
    Abstract    

    Abstract available

  47. EBBINGHAUS D, Banfi G, Selinski S, Blaszkewicz M, et al
    Polymorphisms of xenobiotic metabolizing enzymes in bladder cancer patients of the Semmelweis University Budapest, Hungary.
    J Toxicol Environ Health A. 2017 Jul 11:1-7. doi: 10.1080/10937404.2017.1304736.
    Abstract    

    Abstract available

  48. KRECH E, Selinski S, Blaszkewicz M, Burger H, et al
    Urinary bladder cancer risk factors in an area of former coal, iron, and steel industries in Germany.
    J Toxicol Environ Health A. 2017 Jul 11:1-9. doi: 10.1080/10937404.2017.1304719.
    Abstract    

    Abstract available

  49. LUKAS C, Selinski S, Prager HM, Blaszkewicz M, et al
    Occupational bladder cancer: Polymorphisms of xenobiotic metabolizing enzymes, exposures, and prognosis.
    J Toxicol Environ Health A. 2017 Jul 11:1-14. doi: 10.1080/10937404.2017.1304731
    Abstract    

    Abstract available

  50. YAMAMOTO Y, Suehiro Y, Suzuki A, Nawata R, et al
    Germline DNA copy number variations as potential prognostic markers for non-muscle invasive bladder cancer progression.
    Oncol Lett. 2017;14:1193-1199.
    Abstract    

    Abstract available

  51. SHI J, Zhang X, Shi T, Li H, et al
    Antitumor effects of curcumin in human bladder cancer in vitro.
    Oncol Lett. 2017;14:1157-1161.
    Abstract    

    Abstract available

  52. ZHANG DQ, Zhou CK, Chen SZ, Yang Y, et al
    Identification of hub genes and pathways associated with bladder cancer based on co-expression network analysis.
    Oncol Lett. 2017;14:1115-1122.
    Abstract    

    Abstract available

  53. SHIGEMATSU Y, Oue N, Nishioka Y, Sakamoto N, et al
    Overexpression of the transmembrane protein BST-2 induces Akt and Erk phosphorylation in bladder cancer.
    Oncol Lett. 2017;14:999-1004.
    Abstract    

    Abstract available

  54. SI L, Yang X, Yan X, Wang Y, et al
    Isoliquiritigenin induces apoptosis of human bladder cancer T24 cells via a cyclin-dependent kinase-independent mechanism.
    Oncol Lett. 2017;14:241-249.
    Abstract    

    Abstract available

  55. AUDENET F, Retinger C, Chien C, Benfante NE, et al
    Is restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?
    Urol Oncol. 2017 Jul 6. pii: S1078-1439(17)30302.
    Abstract    

    Abstract available

  56. ROVE KO, Husmann DA, Wilcox DT, Vricella GJ, et al
    Systematic review of bladder cancer outcomes in patients with spina bifida.
    J Pediatr Urol. 2017 Jun 1. pii: S1477-5131(17)30234.
    Abstract    

    Abstract available

  57. ZHONG Z, Huang M, Lv M, He Y, et al
    Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway.
    Cancer Lett. 2017 Jul 4. pii: S0304-3835(17)30409.
    Abstract    

    Abstract available

  58. VALVERDE MARTINEZ S, Salcedo Mercado W, Rodriguez Cruz I, Prieto Nogal SB, et al
    [Urinary tract lymphoepithelial carcinoma. Report of two cases and bibliographic review.]
    Arch Esp Urol. 2017;70:361-366.
    Abstract    

    Abstract available

  59. ORTIZ SANCHEZ L, Alonso Prieto MA, Campanario Perez F, Alvarez-Silva I, et al
    Treatment of urachal disorders: The open and laparoscopic surgery approach.
    Arch Esp Urol. 2017;70:357-360.
    Abstract    

    Abstract available

  60. BALSARA ZR, Li X
    Sleeping beauty: awakening urothelium from its slumber.
    Am J Physiol Renal Physiol. 2017;312:F732-F743.
    Abstract    

    Abstract available

  61. NAKAI Y, Ozawa T, Mizuno F, Onishi S, et al
    Spectrophotometric photodynamic detection involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in voided urine.
    J Cancer Res Clin Oncol. 2017 Jul 19. doi: 10.1007/s00432-017-2476.
    Abstract    

    Abstract available

  62. KANG M, Ku JH
    Emerging role of liquid biopsy of cell-free tumor DNA for bladder cancer surveillance.
    Transl Androl Urol. 2017;6:590-592.
    Abstract    



  63. CHEN C, Hu L, Li X, Hou J, et al
    Preoperative Anemia as a Simple Prognostic Factor in Patients with Urinary Bladder Cancer.
    Med Sci Monit. 2017;23:3528-3535.
    Abstract    

    Abstract available

  64. WARRICK JI, Kaag M, Raman JD, Chan W, et al
    FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
    Virchows Arch. 2017 Jul 18. doi: 10.1007/s00428-017-2190.
    Abstract    

    Abstract available

  65. SMITH AB, Crowell K, Woods ME, Wallen EM, et al
    Functional Outcomes Following Radical Cystectomy in Women with Bladder Cancer: A Systematic Review.
    Eur Urol Focus. 2017;3:136-143.
    Abstract    

    Abstract available

  66. PAL SK, Pham A, Vuong W, Liu X, et al
    Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2017;3:130-135.
    Abstract    

    Abstract available

  67. LUO H, Yang R, Li C, Tong Y, et al
    MicroRNA-139-5p inhibits bladder cancer proliferation and self-renewal by targeting the Bmi1 oncogene.
    Tumour Biol. 2017;39:1010428317718414.
    Abstract    

    Abstract available

  68. EL HAMDANI W, Hadami K, Bensaid M, El Ahanidi H, et al
    Identification of G2607A mutation in EGFR gene with a significative rate in Moroccan patients with Bladder Cancer.
    Cell Mol Biol (Noisy-le-grand). 2017;63:75-81.
    Abstract    

    Abstract available

  69. SRIVASTAVA A, Douglass LM, Chernyak V, Watts KL, et al
    Advances in Imaging in Prostate and Bladder Cancer.
    Curr Urol Rep. 2017;18:69.
    Abstract    

    Abstract available

  70. UTANGAC MM, Yeni E, Savas M, Altunkol A, et al
    Paraoxonase and arylesterase activity in bladder cancer.
    Turk J Urol. 2017;43:147-151.
    Abstract    

    Abstract available

  71. PATEL KM, van der Vos KE, Smith CG, Mouliere F, et al
    Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer.
    Sci Rep. 2017;7:5554.
    Abstract    

    Abstract available

  72. XIE Y, Ma X, Chen L, Li H, et al
    MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis.
    Sci Rep. 2017;7:5619.
    Abstract    

    Abstract available

  73. LAURIDSEN SV, Thomsen T, Thind P, Tonnesen H, et al
    STOP smoking and alcohol drinking before OPeration for bladder cancer (the STOP-OP study), perioperative smoking and alcohol cessation intervention in relation to radical cystectomy: study protocol for a randomised controlled trial.
    Trials. 2017;18:329.
    Abstract    

    Abstract available

  74. LIU T, Li L, Yin L, Yu H, et al
    Superantigen staphylococcal enterotoxin C1 inhibits the growth of bladder cancer.
    Biosci Biotechnol Biochem. 2017 Jul 17:1-6. doi: 10.1080/09168451.2017.1350564.
    Abstract    

    Abstract available

  75. CAO HL, Liu ZJ, Chang Z
    Cordycepin induces apoptosis in human bladder cancer cells via activation of A3 adenosine receptors.
    Tumour Biol. 2017;39:1010428317706915.
    Abstract    

    Abstract available

  76. GOURD E
    TERT mutations in urine could predict bladder cancer recurrence.
    Lancet Oncol. 2017 Jul 13. pii: S1470-2045(17)30538.
    Abstract    



  77. MONTANO R, Khan N, Hou H, Seigne J, et al
    Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor.
    Oncotarget. 2017 Jun 28. doi: 10.18632/oncotarget.18834.
    Abstract    

    Abstract available

  78. YUAN D, Zheng S, Wang L, Li J, et al
    MiR-200c inhibits bladder cancer progression by targeting lactate dehydrogenase A.
    Oncotarget. 2017 Jun 28. doi: 10.18632/oncotarget.18801.
    Abstract    

    Abstract available

  79. KUSAKA A, Hatakeyama S, Hosogoe S, Hamano I, et al
    Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer.
    Oncotarget. 2017 Jul 6. doi: 10.18632/oncotarget.19043.
    Abstract    

    Abstract available

  80. LI C, Ge Q, Liu J, Zhang Q, et al
    Effects of miR-1236-3p and miR-370-5p on activation of p21 in various tumors and its inhibition on the growth of lung cancer cells.
    Tumour Biol. 2017;39:1010428317710824.
    Abstract    

    Abstract available

  81. NAGAI T, Kamimura T, Itou K, Fujii M, et al
    Myopericytoma in urinary bladder: a case report.
    J Med Case Rep. 2017;11:46.
    Abstract    

    Abstract available

  82. JORGENSEN KR, Hoyer S, Sorensen MM, Jensen JB, et al
    Human papillomavirus types 44, 52, 66 and 67 detected in a woman with squamous cell carcinoma of the urinary bladder.
    Scand J Urol. 2017;51:85-86.
    Abstract    

    Abstract available

  83. ANDREASSEN BK, Myklebust TA, Haug ES
    Crude mortality and loss of life expectancy of patients diagnosed with urothelial carcinoma of the urinary bladder in Norway.
    Scand J Urol. 2017;51:38-43.
    Abstract    

    Abstract available

  84. LIEDBERG F, Ahlgren G, Baseckas G, Gudjonsson S, et al
    Long-term functional outcomes after radical cystectomy with ileal bladder substitute: does the definition of continence matter?
    Scand J Urol. 2017;51:44-49.
    Abstract    

    Abstract available

  85. ORYWAL K, Jelski W, Werel T, Szmitkowski M, et al
    The Diagnostic Significance of Serum Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in Urinary Bladder Cancer Patients.
    Anticancer Res. 2017;37:3537-3541.
    Abstract    

    Abstract available

  86. MCCOMBIE SP, Bangash HK, Kuan M, Thyer I, et al
    Delays in the diagnosis and initial treatment of bladder cancer in Western Australia.
    BJU Int. 2017 Jun 29. doi: 10.1111/bju.13939.
    Abstract    

    Abstract available

  87. SOAVE A, Riethdorf S, Dahlem R, Minner S, et al
    Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy.
    BJU Int. 2017;119:854-861.
    Abstract    

    Abstract available

  88. DESCOTES F, Kara N, Decaussin-Petrucci M, Piaton E, et al
    Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.
    Br J Cancer. 2017 Jul 6. doi: 10.1038/bjc.2017.
    Abstract    

    Abstract available

  89. OJERHOLM E, Smith A, Hwang WT, Christodouleas JP, et al
    Reply to Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.
    Cancer. 2017 Jun 30. doi: 10.1002/cncr.30871.
    Abstract    



  90. DOLAN RD, McMillan DC
    Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.
    Cancer. 2017 Jun 30. doi: 10.1002/cncr.30872.
    Abstract    



  91. GILD P, Ehdaie B, Kluth LA
    Effect of obesity on bladder cancer and renal cell carcinoma incidence and survival.
    Curr Opin Urol. 2017 Jun 24. doi: 10.1097/MOU.0000000000000425.
    Abstract    

    Abstract available

  92. SAFIRI S, Ayubi E
    Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Expe
    Eur Urol. 2017 Jun 22. pii: S0302-2838(17)30503.
    Abstract    



  93. BOSSCHIETER J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, et al
    Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Eur Urol. 2017 Jul 10. pii: S0302-2838(17)30538.
    Abstract    

    Abstract available

  94. BOTTERI E, Ferrari P, Roswall N, Tjonneland A, et al
    Alcohol consumption and risk of urothelial cell bladder cancer in the European Prospective Investigation into Cancer and Nutrition cohort.
    Int J Cancer. 2017 Jul 19. doi: 10.1002/ijc.30894.
    Abstract    

    Abstract available

  95. YAMASHITA T, Higashi M, Momose S, Morozumi M, et al
    Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer.
    Int J Oncol. 2017;51:579-586.
    Abstract    

    Abstract available

  96. WANG CY, Xu ZB, Wang JP, Jiao Y, et al
    Rb deficiency accelerates progression of carcinoma of the urinary bladder in vivo and in vitro through inhibiting autophagy and apoptosis.
    Int J Oncol. 2017;50:1221-1232.
    Abstract    

    Abstract available

  97. LIU Z, Liu J, Zhao L, Geng H, et al
    Curcumin reverses benzidine-induced epithelial-mesenchymal transition via suppression of ERK5/AP-1 in SV-40 immortalized human urothelial cells.
    Int J Oncol. 2017;50:1321-1329.
    Abstract    

    Abstract available

  98. VAN DE PUTTE EEF, Vegt E, Mertens LS, Bruining A, et al
    FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.
    Int Urol Nephrol. 2017 Jul 3. doi: 10.1007/s11255-017-1637.
    Abstract    

    Abstract available

  99. ARK JT, Alvarez JR, Koyama T, Bassett JC, et al
    Variation in the diagnostic evaluation among persons with hematuria: influence of gender, race, and risk factors for bladder cancer.
    J Urol. 2017 Jun 24. pii: S0022-5347(17)76746-8. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  100. WANG S, Liu B, Zhang J, Sun W, et al
    Centromere protein U is a potential target for gene therapy of human bladder cancer.
    Oncol Rep. 2017 Jun 30. doi: 10.3892/or.2017.5769.
    Abstract    

    Abstract available

  101. WANG SC, Wang ST, Liu HT, Wang XY, et al
    Trichostatin A induces bladder cancer cell death via intrinsic apoptosis at the early phase and Sp1survivin downregulation at the late phase of treatment.
    Oncol Rep. 2017 Jul 6. doi: 10.3892/or.2017.5795.
    Abstract    

    Abstract available

  102. MONCRIEF TJ, Balaji P, Lindgren B, Weight CJ, et al
    Comparative Evaluation of Bladder Specific Health Related Quality of Life (HRQOL) Instruments for Bladder Cancer.
    Urology. 2017 Jul 10. pii: S0090-4295(17)30698.
    Abstract    

    Abstract available

  103. DYSHLOVOY SA, Madanchi R, Hauschild J, Otte K, et al
    The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.
    BMC Cancer. 2017;17:93.
    Abstract    

    Abstract available

  104. MASOOMPOUR SM, Lankarani KB, Honarvar B, Tabatabaee SH, et al
    Changing Epidemiology of Common Cancers in Southern Iran, 2007-2010: A Cross Sectional Study.
    PLoS One. 2016;11:e0155669.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;